Skip to main content
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?

Leiden po

Dr. John Cush RheumNow

1 year 1 month ago
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/bwXgrB875k
Clinical determinants of multiple drug failure in D2T RA
2000+ RA cohort 250+ refractory
-Low financial status
-Cancer

Dr. John Cush RheumNow

1 year 1 month ago
Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer Hx -CV comorbidities -Chronic use of NSAID or GCs Protective: Regular participation in leisure activities #POS0030 @RheumNow #EULAR2025 https://t.co/mdePGkHU82
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA

At a EULAR 2025 session titled “What m

Dr. John Cush RheumNow

1 year 1 month ago
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/Qy9fy3GWKm
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-IL

Dr. John Cush RheumNow

1 year 1 month ago
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD. #EULAR2025 @RheumNow https://t.co/HC0skwUKQG
Foot and ankle #OA is often underrecognized..
1 in 6 people over 50 have foot OA!
#EULAR2025 @RheumNow https://t.co/4wGS

Dr. John Cush RheumNow

1 year 1 month ago
Foot and ankle #OA is often underrecognized.. 1 in 6 people over 50 have foot OA! #EULAR2025 @RheumNow https://t.co/4wGSzC8dvi
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-known cousins. Now, however, we are seeing a discordance and following GPA/MPA management will potentially lead to both over-treatment and suboptimal
Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.
How to patients with rheumatic diseases consume online health information?
78% used internet for health information
50%

Dr. John Cush RheumNow

1 year 1 month ago
How to patients with rheumatic diseases consume online health information? 78% used internet for health information 50% use it atleast a month 66% found online information superior 41% used social media! 80% using it to find treatment optio ns! @rheumnow #EULAR2025 https://t.co/ZcjwPaqsjT
FDA approves new drug for MAS in Still's disease. Gamifant (emapalumab-lzsg) is interferon gamma (IFNγ)–blocking Ab a

Dr. John Cush RheumNow

1 year 1 month ago
FDA approves new drug for MAS in Still's disease. Gamifant (emapalumab-lzsg) is interferon gamma (IFNγ)–blocking Ab approved For HLH, now for use in adults & children w/ Still's Dz complicated by Macrophage Activation Syndrome. https://t.co/3div1fktWU https://t.co/VvSkuEoki5
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Gre

Dr. John Cush RheumNow

1 year 1 month ago
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/yzQVt1fLKW https://t.co/kiX6kPPQP5
#EULAR2025 in numbers

💫5125 abstracts submitted from 95 countries
💫177 scientific sessions
💫350 speakers from

Dr. John Cush RheumNow

1 year 1 month ago
#EULAR2025 in numbers 💫5125 abstracts submitted from 95 countries 💫177 scientific sessions 💫350 speakers from 45 nations 💫Balanced gender split of speakers & chairpersons 💫Fresh sessions format 💫Integration of European Workshop for Rheum Research https://t.co/7WoknFuVLL
×